Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) CFO Paul Herendeen purchased 15,000 shares of the firm’s stock in a transaction on Tuesday, March 13th. The shares were purchased at an average price of $16.10 per share, for a total transaction of $241,500.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Valeant Pharmaceuticals Intl Inc (VRX) opened at $16.40 on Wednesday. Valeant Pharmaceuticals Intl Inc has a 52 week low of $8.31 and a 52 week high of $24.43. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 4.25. The firm has a market capitalization of $5,600.00, a price-to-earnings ratio of 3.95, a price-to-earnings-growth ratio of 0.53 and a beta of -0.28.
Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $0.98 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.96 by $0.02. Valeant Pharmaceuticals Intl had a return on equity of 42.48% and a net margin of 27.56%. The company had revenue of $2.16 billion for the quarter, compared to analysts’ expectations of $2.18 billion. During the same period last year, the firm earned $1.26 earnings per share. Valeant Pharmaceuticals Intl’s quarterly revenue was down 10.0% on a year-over-year basis. equities research analysts predict that Valeant Pharmaceuticals Intl Inc will post 3.12 EPS for the current year.
A number of institutional investors have recently bought and sold shares of VRX. Prime Capital Investment Advisors LLC purchased a new position in shares of Valeant Pharmaceuticals Intl during the fourth quarter worth about $142,000. Sheaff Brock Investment Advisors LLC purchased a new position in shares of Valeant Pharmaceuticals Intl during the fourth quarter worth about $200,000. Cetera Investment Advisers purchased a new position in shares of Valeant Pharmaceuticals Intl during the fourth quarter worth about $208,000. Keybank National Association OH purchased a new position in shares of Valeant Pharmaceuticals Intl during the fourth quarter worth about $208,000. Finally, Traynor Capital Management Inc. purchased a new position in shares of Valeant Pharmaceuticals Intl during the fourth quarter worth about $213,000. Institutional investors own 50.12% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.tickerreport.com/banking-finance/3261325/paul-herendeen-purchases-15000-shares-of-valeant-pharmaceuticals-intl-inc-vrx-stock.html.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.